Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00101452 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

A NA study of Depression, sponsored by Maurizio Fava, MD.

Completed
Registry status
NA
Development phase
199
Enrollment target
2
Study locations

NCT00101452 is a NA study of Depression that has completed, run by Maurizio Fava, MD. The registered enrollment target is 199 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00101452, a NA study of Depression, has completed, sponsored by Maurizio Fava, MD.

COMPLETED
Registry status
NA
Development phase
199 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the safety and effectiveness of s-adenosyl-l-methionine (SAMe) in treating major depression.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Escitalopram
  • DRUG S-adenosyl-l-methionine

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

Rhode Island

  • Butler Hospital - Providence

Trial Details

FieldValue
Enrollment Target 199 participants
Start Date 2005-04
Est. Completion 2010-06
Phase NA

Sponsor

Maurizio Fava, MD

4 total trials

What the Registry Record Tells You About NCT00101452

The ClinicalTrials.gov registry entry for NCT00101452 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (75% lower). The listed sponsor is Maurizio Fava, MD, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00101452 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00101452 about?

NCT00101452 is a clinical study titled "Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression". The purpose of this study is to determine the safety and effectiveness of s-adenosyl-l-methionine (SAMe) in treating major depression.

What is the current status of trial NCT00101452?

This trial is currently completed. It is a NA study. The enrollment target is 199 participants. The study started on 2005-04. Estimated completion is 2010-06.

What conditions does trial NCT00101452 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT00101452?

The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), S-adenosyl-l-methionine (DRUG).

Who is sponsoring clinical trial NCT00101452?

This trial is sponsored by Maurizio Fava, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00101452 being conducted?

This trial has 2 study locations across Massachusetts, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.